Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

AstraZeneca Says FDA Asks For Seroquel Detail

By Pharmaceutical Processing | December 24, 2008

LONDON (AP) – AstraZeneca PLC said Wednesday that the U.S. Food and Drug Administration has asked for more information regarding the drug Seroquel, which AstraZeneca is trying to get approved for use by people suffering from depression. Seroquel XR, one of AstraZeneca’s best-selling drugs, is currently approved in the U.S. only for the treatment of people with schizophrenia or bipolar disorder, a disease characterized by dramatic and severe mood swings. But AstraZeneca has applied to the FDA to market the drug for the treatment of major depressive disorder in adult patients. The London-based drug maker said that FDA has sought more information in a so-called complete response letter (CRL) to that application. “AstraZeneca is evaluating the contents of the CRL and the proposed labeling revisions,” the company said in a statement to the London Stock Exchange. “AstraZeneca will continue discussions with the FDA and will provide a response to the agency in due course.” The company said it did not yet know if, or when, the drug would get approval for treating depression. “At this point in time, we don’t know if this means that there will or there won’t be a delay, or whether this could lead to no approval,” said Sarah Lindgreen, spokeswoman for AstraZeneca. AstraZeneca said the FDA letter does not change the current recommendations for the treatment of patients using the drug for schizophrenia or bipolar disorder. Seroquel is AstraZeneca’s second-best seller behind heartburn drug Nexium, raking in US$4 billion in sales last year. AstraZeneca earlier this year won a key decision in a U.S. court that means that generic copies of the drug will not be launched any time soon.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE